Monica Holmberg

4 days ago | pharmacytimes.com | Monica Holmberg

The FDA has approved suzetrigine oral tablets (Journavx; Vertex Pharmaceuticals Inc), a nonopioid oral pain signal inhibitor, for the treatment of moderate to severe acute pain in adults.1,2 Common causes of acute pain include accident, injury, or surgery.

1 month ago | pharmacytimes.com | Monica Holmberg

The FDA approved an additional indication for tirzepatide injection (Zepbound; Eli Lilly and Company) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity when used with a reduced-calorie diet and increased physical activity.

2 months ago | pharmacytimes.com | Monica Holmberg

The FDA has approved sulopenem etzadroxil and probenecid oral tablets (Orlynvah; Iterum Therapeutics) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in women who have limited or no alternative oral antibacterial treatment options.1 An estimated 60% of women will have a uUTI during their lifetime, and approximately 40% will experience a recurrence.

Mar 21, 2025 | pharmacytimes.com | Monica Holmberg

Publication Article March 21, 2025 Pharmacy Times March 2025Volume91 Issue 3 Author(s): The FDA has approved epinephrine nasal spray (neffy; ARS Pharmaceuticals, Inc) for the emergency treatment of type I allergic reactions, including anaphylaxis, in adults and pediatric patients with a weight of 30 kg or more.1 Of the 40 million individuals in the US who are affected by type I severe allergic reactions, only 3.3 million have an active epinephrine auto-injector prescription, and of those,...

Feb 26, 2025 | pharmacytimes.com | Monica Holmberg

The FDA has approved xanomeline and trospium chloride oral capsules (Cobenfy; Bristol Myers Squibb) for the treatment of schizophrenia in adults.1 Schizophrenia affects approximately 2.8 million individuals in the US and 24 million people around the globe, with initial symptoms usually occurring in early adulthood. It is among the top 15 leading causes of disability worldwide.2PHARMACOLOGY AND PHARMACOKINETICSXanomeline is an M1 and M4 muscarinic acetylcholine receptor agonist.